IRVING, Texas, Feb. 9, 2021 – Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence, focused on fulfilling the promise of precision medicine, announced today that David D. Halbert, Chairman and Chief Executive Officer, Brian J. Brille, Vice Chairman, David Spetzler, MS, MBA, Ph.D., President and Chief Scientific Officer and Thomas Parker, Senior Vice President and Chief Financial Officer will host a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference February 17, 2021, at 4:00 p.m. Eastern time.
Mr. Halbert, Mr. Brille, Dr. Spetzler and Mr. Parker will provide an overview of Caris’ business, along with its suite of market-leading molecular profiling offerings, and discuss recent corporate growth initiatives that position Caris to further extend its leadership position in the market.
About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.
Caris is also advancing precision medicine with Caris MAI™ (Molecular Artificial Intelligence) that combines its innovative service offerings, Caris Molecular Intelligence® with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.
Caris Pharmatech is changing the paradigm and streamlines the clinical trial process by assisting biopharma companies with accessing research-ready oncology sites for clinical trials. With over 350 research sites within the Caris Pharmatech Just-In-Time (JIT) Oncology Network, biopharma companies can identify and enroll more patients, faster. Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process. By implementing Caris’ Just-In-Time Trial-Matching System, Caris will automatically match patients to clinical trials and sites can be activated and eligible to enroll patients within one week.
Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Media and Investor Relations Contact:
Corporate Development Contact:
Caris Life Sciences
Caris Life Sciences Media Contact: